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Safety of fluoxetine use in children and adolescents: a disproportionality analysis 
of the Food and Drug Administration Adverse Event Reporting System database
Dear Editor,  
 
Fluoxetine, a selective serotonin reuptake inhibitor 
(SSRI) is currently the only licensed SSRI recommended 
in combination with cognitive behavioural therapy to 
treat depression in those under 18 years of age. (1) In 
2004, a black box warning communicating the increased 
risk of suicidal thinking and behaviour compared to 
placebo in children and adolescents was added to the 
labelling of all antidepressants. (2) In this letter, we 
assess the overall safety of fluoxetine by analysing the 
reports of adverse events in children and adolescents 
using fluoxetine, submitted to the FDA Adverse Event 
Reporting System (FAERS) between 01-Jan-2015 to 30-
Jun-2019.   
We performed a case/non-case analysis on the 
top 10 most reported adverse events for fluoxetine users 
under 18 years old. Cases were reports which included at 
least one of the top 10 adverse events, whereas non-cases 
were all remaining reports. Reporting odds ratio (ROR), 
with  95% confidence intervals was calculated for each 
of the top 10 most frequently reported adverse events, 
shown in Figure 1.  We used the PharmaPendium® (3) 
database (which extracts data directly from FAERS) to 
export the relevant data into an excel spreadsheet. We 
then used R 3.6.1 statistical software to calculate ROR, 
which compared patients within the same age and study 
date range. Reports in FAERS can be submitted by 
lawyers, consumers, physicians, pharmacists and other 
healthcare professionals. We verified the preferred terms 
from the Medical Dictionary for Regulatory Activities 
(MedDRA), version 22.1, and retrieved reports as per the 
preferred term. 
Our analysis identified 359 adverse event 
reports (01-Jan-2015 - 30-Jun-2019), after de-
duplication. In order of decreasing frequency of events, 
the top 10 adverse event reports were: ‘foetal exposure 
during pregnancy’ (n=128), ‘suicidal ideation’ (n=63), 
‘suicidal attempt’ (n=49), ‘anxiety’ (n=42), ‘serotonin 
syndrome’ (n=42), ‘vomiting’ (n=38), ‘intentional self-
injury’ (n=38), ‘atrial septal defect’ (n=35), depression 
(n=34) and ‘seizure’ (n=31).  
Our study identified expected and unexpected 
findings. Findings were expected if the electronic 
medicines compendium (emc) (1) lists the specific 
adverse event as a “common” adverse event. Expected 
signals were found for ‘serotonin syndrome’ ROR = 
22.06, 95% CI = 15.88-30.64, ‘intentional self-injury’ 
ROR = 7.41, 95% CI = 5.34 – 10.3, ‘suicidal ideation’ 
ROR = 6.19, 95% CI = 4.8 – 7.99, ‘foetal exposure 
during pregnancy’ (ROR = 5.13, CI = 4.29 – 6.14), 
‘suicide attempt’ ROR = 4.5, 95% CI = 3.38 – 5.99, 
‘depression’ ROR = 2.84, 95% CI = 2.02 – 4 and  
‘anxiety’ (ROR = 2.51, 95% CI = 1.85 – 3.42). 
‘Vomiting’ (ROR = 0.68, 95% CI = 0.49-0.93 ) and 
‘seizure’ ( ROR = 0.91, 95% CI = 0.64-1.30) did not 
show disproportionate signals.  
Our study identified the known link between 
maternal fluoxetine use and ‘atrial septal defects’ (ASD),  
ROR = 8.36, 95% CI = 5.93 -  11.79);  27.3% of foetuses 
exposed to fluoxetine during pregnancy had ASD’s. The 
remaining cases, however, were for 9 to 18-year-olds 
(still undergoing cardiac development). The emc does 
not warn for ASD for those exposed to fluoxetine who 
are under 18 years old. There are zero cases of ASD for 
those older than 19 years old, indicating a potential link 
between the developing myocardium and ASD. There is 
biological plausibility explaining why adolescents are 
more prone to ASD compared to adults; serotonin 
regulates key cellular processes in cardiac development, 
and fluoxetine can inhibit proliferation of the 
myocardium and cushion mesenchyme cells. (4) Another 
study compared the safety profile of fluoxetine in 
combination with olanzapine in adolescents and adults. 
However, ASD with fluoxetine use was not examined. 
(5)  The higher reporting of ASD among children 
exposed to fluoxetine in our study is important for 
advancing paediatric pharmacoepidemiology research.  
Further confirmation from a large case-control study is 
needed to validate this adverse effect.  
22.06































Figure 3.  Reporting odds ratio (ROR) with  95% confidence intervals (95% CI) for the top 10 adverse events reported 
in the FAERS database between 01-Jan-2015 and 30-Jun-2019 for under 18-year-old fluoxetine users. 
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